ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The survey found that over 50% of women learned about the effects of menopause on the skin by going through it themselves, with most finding out about it in their 40s. However, over 30% wo ...

Core Viewpoint - The global beauty and medical aesthetics industries are deeply integrating, with Galderma leveraging its unique positioning of "pharmaceuticals + medical aesthetics + skincare" to seize strategic opportunities. This integrated approach aligns with the industry's trend towards "health + aesthetics" [2][4]. Group 1: Company Overview - Galderma has transformed from a skin care company known for selling Cetaphil to a major player in the pharmaceutical and medical aesthetics sectors since its independence from Nestlé in 2019. It is now the largest independent dermatology company globally, operating in over 100 countries with more than 7,000 employees [4][21]. - The company's annual revenue has grown from approximately $3.5 billion in 2020 to over $4 billion, with projections reaching $4.41 billion by 2024. In the first half of 2025, revenue reached $2.448 billion, reflecting a 12.2% growth at constant exchange rates [4][6]. Group 2: Business Segments - Galderma's growth is driven by three main business segments: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. In the first half of 2025, these segments generated sales of $1.24 billion, $719 million, and $489 million, respectively, with growth rates of 9.8%, 7.7%, and 26.9% [6][7]. - The Injectable Aesthetics segment, which includes products like neurotoxins and fillers, is the highest revenue contributor, while the Therapeutic Dermatology segment shows significant growth potential, particularly with FDA-approved products [6][8]. Group 3: Market Trends and Consumer Behavior - The beauty industry is entering a "performance-driven" era, with consumers increasingly favoring value-oriented brands and prioritizing ingredient transparency and efficacy. This trend is particularly evident among Gen Z consumers [8][11]. - In the medical aesthetics sector, the demand for injectables is surging due to trends like the "Ozempic face" phenomenon and the aging baby boomer population. Galderma's products, such as Relydess and Sculptra, are well-positioned to capitalize on this growth [8][9]. Group 4: Strategic Positioning in China - China represents the largest and most promising skincare market globally, with a projected market size of 1,073.8 billion RMB in 2024. Galderma's Cetaphil brand aligns well with the increasing demand for effective, clinically-backed skincare products [11][16]. - The company is also expanding its injectable aesthetics offerings in China, with products like Relydess and Sculptra, responding to the rising demand for anti-aging solutions [15][16]. Group 5: Future Outlook - Galderma's robust R&D capabilities and capital support position it for sustained growth over the next decade. The company has a global R&D network with over 650 personnel and has conducted more than 770 clinical trials for its products since 2020 [23][24]. - With its integrated strategy of "pharmaceuticals + medical aesthetics + skincare," Galderma is well-positioned to potentially enter the top 10 global beauty groups and become a core player in the dual beauty and medical aesthetics market [24].

Group 1: Med Spa Industry Overview - The med spa industry has experienced significant growth, expanding sixfold from 2010 to 2023, with over 10,000 locations in the U.S. and average annual revenue per spa nearing $1.5 million [33] - In 2023, the med spa market was valued at $15 billion, with projections indicating a 15% annual growth rate moving forward [34] - The industry is characterized by a mix of medical and spa services, requiring medical professionals for certain procedures, but with relatively low barriers to entry [32] Group 2: Investment Opportunities - Limited direct investment opportunities exist in the med spa business, as many are privately held, but there are opportunities in the products sold, particularly dermal fillers and neurotoxins [34][35] - AbbVie, the owner of Botox, and Evolus, which specializes in aesthetic products like Jeuveau, are key players in this market, with Evolus expected to expand its product line to include fillers [35][37] - Evolus' unique cash pay business model allows for greater flexibility in pricing and marketing compared to competitors, potentially leading to higher profitability for injectors [36] Group 3: Competitive Landscape - Botox remains the market leader with a market share in the mid-60s, but faces increasing competition from Evolus and other neurotoxins, which have been gaining market share [39] - Evolus has reported a 30% year-over-year sales growth for Jeuveau, indicating strong demand and market penetration [39] - The overall market for neurotoxins and fillers is expected to grow at high single-digit to low double-digit rates, driven by increasing consumer demand [39]